AMPH Amphastar Pharmaceuticals, Inc.

8-K Current Report

Filed: March 6, 2026

Health Care

Pharmaceutical Preparations

Amphastar Pharmaceuticals, Inc. Overview

Amphastar Pharmaceuticals, Inc. (AMPH) 8-K current report filed with SEC EDGAR on March 6, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 1.01: Entry into a Material Definitive Agreement

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Supply Agreement with Letop (March 3, 2026): ANP sources chemical intermediates; 5-year term, no minimum purchase obligation, payments in Chinese yuan
• Related party risk: Letop majority-owned by Henry Zhang, son of CEO Dr. Jack Zhang and COO Dr. Mary Luo — Audit Committee approval required and obtained

+3 more insights

Other Amphastar Pharmaceuticals, Inc. 8-K Filings

8-K Mar 16, 2026

8-K Mar 6, 2026

8-K Feb 26, 2026

Get deeper insights on Amphastar Pharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.